Egyptian International Pharmaceutical Investments (CAI:PHAR) Cyclically Adjusted FCF per Share: E£-5.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
71 GF Score
Price E£96.50
GF Value E£59.95
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Cyclically Adjusted FCF per Share?

Egyptian International Pharmaceutical Investments CAI:PHAR +3.32% 71 Cyclically Adjusted FCF per Share is E£-5.21 as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 71/100 and a GF Value™ of E£59.95 (Significantly Overvalued). The stock has 12 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Egyptian International Pharmaceutical Investments's adjusted free cash flow per share for the three months ended in Mar. 2026 was E£-8.160. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is E£-5.21 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-30), Egyptian International Pharmaceutical Investments's current stock price is E£96.50. Egyptian International Pharmaceutical Investments's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was E£-5.21. Egyptian International Pharmaceutical Investments's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Egyptian International Pharmaceutical Investments was 106.94. The lowest was 9.20. And the median was 13.25.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Egyptian International Pharmaceutical Investments was 106.94. The lowest was 9.20. And the median was 13.25.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Egyptian International Pharmaceutical Investments Cyclically Adjusted FCF per Share Related Terms


Egyptian International Pharmaceutical Investments Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Cyclically Adjusted FCF per Share Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.48 1.69 -0.17 -3.24

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.24 -3.46 -3.97 -4.25 -5.21

CAI:PHAR vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Cyclically Adjusted Price-to-FCF falls into.


CAI:PHAR
71GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egyptian International Pharmaceutical Investments's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-8.16/330.2130*330.2130
=-8.160

Current CPI (Mar. 2026) = 330.2130.

Egyptian International Pharmaceutical Investments Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 1.321 238.132 1.832
201606 1.060 241.018 1.452
201609 1.175 241.428 1.607
201612 1.157 241.432 1.582
201703 1.145 243.801 1.551
201706 -0.448 244.955 -0.604
201709 0.774 246.819 1.036
201712 0.152 246.524 0.204
201803 0.997 249.554 1.319
201806 -1.492 251.989 -1.955
201809 0.427 252.439 0.559
201812 -0.026 251.233 -0.034
201903 0.123 254.202 0.160
201906 2.661 256.143 3.430
201909 2.474 256.759 3.182
201912 -3.084 256.974 -3.963
202003 3.008 258.115 3.848
202006 -2.444 257.797 -3.131
202009 -1.555 260.280 -1.973
202012 2.242 260.474 2.842
202103 -0.594 264.877 -0.741
202106 -0.678 271.696 -0.824
202109 2.642 274.310 3.180
202112 1.607 278.802 1.903
202203 -0.686 287.504 -0.788
202206 -0.629 296.311 -0.701
202209 -2.833 296.808 -3.152
202212 -2.520 296.797 -2.804
202303 -3.852 301.836 -4.214
202306 -8.748 305.109 -9.468
202309 -3.650 307.789 -3.916
202312 -0.217 306.746 -0.234
202403 -15.475 312.332 -16.361
202406 -5.126 314.175 -5.388
202409 -3.805 315.301 -3.985
202412 -3.296 315.605 -3.449
202503 -0.503 319.799 -0.519
202506 -4.136 322.561 -4.234
202509 -1.153 324.800 -1.172
202603 -8.160 330.213 -8.160

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of E£-5.21 mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Cyclically Adjusted FCF per Share of E£-5.21 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Cyclically Adjusted FCF per Share too high?
Egyptian International Pharmaceutical Investments' current Cyclically Adjusted FCF per Share is E£-5.21. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Cyclically Adjusted FCF per Share of E£-5.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Cyclically Adjusted FCF per Share is E£-5.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.95, compared to a current price of E£96.50 — trading 61% above its estimated fair value. The current Cyclically Adjusted FCF per Share is E£-5.21. Egyptian International Pharmaceutical Investments' overall GF Score™ is 71/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Cyclically Adjusted FCF per Share is E£-5.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£96.50 is trading 61% above its estimated GF Value™ of E£59.95. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Cyclically Adjusted FCF per Share: E£-5.21
  • GF Value™: E£59.95 vs. price of E£96.50 (61% above fair value)
  • GF Score™: 71/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
71GF Score

Get the complete analysis for CAI:PHAR

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£96.50
Price
E£59.95
GF Value